Unilife is an emerging leader in innovative drug delivery devices. They develop technologies like their Unifill prefilled syringe platform, which is the first with integrated safety features. Unifill is now in production and being shipped to customers like Sanofi. Unilife focuses on collaborating with drug companies to develop customized device solutions that can enhance drugs from clinical trials through commercialization. Their goal is to introduce differentiated devices that provide benefits for patients and partners.

1. Innovative Drug
Delivery Device
Solutions
Ramin Mojdeh, Ph.D.
Executive Vice President and
Chief Operating Officer
UBS Specialty Pharma Conference
May 2011

2. Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward looking statements under the
safe harbor provisions of the US securities laws. These forward-
looking statements are based on management’s beliefs and
assumptions and on information currently available to our
management. Our management believes that these forward-
looking statements are reasonable as and when made. However
you should not place undue reliance on any such forward looking
statements as these are subject to risks and uncertainties. Please
refer to our press release and our SEC filings for more information
regarding the use of forward looking statements.
2

3. Introducing Unilife
Emerging global leader in innovative drug delivery device solutions
Enable and enhance delivery of drugs by pharmaceutical customers
Rapidly expanding pipeline being driven by customer needs
Unifill – world’s only prefilled platform with integrated safety
NASDAQ listed (UNIS) with state-of-the-art facility in York, PA
3

4. Attractive Market Trends and Opportunity
$30B Injectable drug delivery device market in 2015, 12.3% CAGR
Large macromolecule composition of pharmaceutical pipeline
Safety legislation and sharps management
Devices drive patient acceptance, preference and adherence
Emerging healthcare needs of aging global population
Rising global healthcare standards creating strong market potential
Improved outcomes and economics with use of unit-dose and ready to
administer formats
Trend to patients self-administration of injectable drugs
Patent cliff - 30 biologics with $51B sales expire by 2015
4

5. Strategic Focus
Innovative device solutions for commercial drugs/biosimilars
Integrated proprietary primary drug delivery devices with value-add features
Target and address emerging unmet needs for pipeline drugs
Pharmaceutical collaborations – specialized devices for novel drugs
Target high-end of market for differentiated devices, high margins
Strategic sourcing of components
In-house manufacturing and final assembly
5

6. Customer-Driven Technology Pipeline
Technology pipeline developed in partnership with customers
Directly responding to emerging customer needs including:
Integrated primary drug delivery devices with value-add features and
customization
Advanced syringe systems with integrated safety and transfer mechanisms
Dry drug reconstitution and delivery technologies
Large-volume viscous drugs delivery technologies
Targeted organ delivery devices
Multi-chamber proprietary primary containers and delivery systems
Reusable and disposable self administration device technologies
Technology portfolio can be leveraged to develop customized
device concepts according to specific customer needs
6

7. Unifill – The Leading Edge of Our Portfolio
World’s first and only prefilled syringes with integrated safety
Now in production
Controlled retraction into barrel
Needle locked after use for convenient, compact disposal
7

8. Unifill as a Game Changer
2.5B Units Annually Primary drug delivery
device with integrated
safety
Ancillary
+ safety
needle Unifill Direct substitute for
Platform
current prefill and safety
Standard Current prefill syringes
Prefill Safety
Syringe Syringe
Direct
Substitute Powerful brand
differentiation
Ancillary
Streamlines fill-finish
+ safety
Device
and packaging process
Optimal protection
Standard Current
Prefill Safety
Syringe Syringe
8

9. Success in the Face of a Big Challenge
Technology solves a technical challenge most thought impossible
Sanofi invested $40MM for access rights to Unifill
Ready for initial shipment in July – well ahead of original
schedule
Current capacity of 60MM units, planned 150MM unit line
extension
9

10. New Paradigm in Drug-Device Development
Clinical Development (phase I, II, III) Approval Sales
Patient
requirements
Drug
industrialization
requirements
Customized
delivery device
Devices customized to specific requirements of drugs and target
patients
Collaboration with drug companies from clinical development
through commercial sales
Unique devices increasingly used to differentiate brands,
optimize product lifecycles and enhance patient care
10

11. Summary
Unilife - emerging global leader in innovative drug delivery devices
Injectable drug delivery device market is attractive and growing fast
Innovative, differentiated devices for pipeline drugs and biosimilars
Developing rich portfolio of technologies driven by customer need
Unifill: the 1st and only prefill syringe system with integrated safety
The new drug-device paradigm is to target pipeline drugs to develop
total system solutions for the pharmaceutical partner
Launch with Unifill, then drive growth with successive introductions
of innovative, differentiated devices
11